Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
PR Newswire•07/10/2026•08:00 ET
0
Key Highlights
- ➤Immunic will present four new vidofludimus calcium clinical, biomarker and preclinical analyses.
- ➤CALLIPER extension data show disability outcomes favoring continuous treatment through week 48.
- ➤CALLIPER analysis found statistically significant results for a bidirectional disability-change endpoint.
- ➤Phase 3 relapsing MS top-line data are expected by the end of 2026.
- ➤Additional Phase 3 progressive MS trial initiation is expected later in 2026.
Expert Statements
Erik Lundgren, Chief Executive Officer of Immunic
“The four presentations at MSToronto2026 add to the growing clinical and mechanistic evidence supporting the differentiated profile of vidofludimus calcium across the multiple sclerosis (MS) spectrum.”
Erik Lundgren, Chief Executive Officer of Immunic
“The new CALLIPER open-label extension outcomes provide favorable long-term follow-up data of disability outcomes in progressive MS, while the Nurr1, Epstein-Barr virus (EBV) and disability endpoint analyses further deepen our understanding of vidofludimus calcium's potential to address both inflammatory disease activity and disability progression.”
Erik Lundgren, Chief Executive Officer of Immunic
“We look forward to presenting these findings to the MS community later this month.”
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting PR Newswire
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability Measurement, and Nurr1-Mediated Neuronal Survival –
Get started
Create a free account to read the full story.